Tenderwize
Retour à la recherche

Framework agreement for CAR-T cell therapy active ingredients

Azienda ULSS n. 8 Berica·Vicenza, Italy·EUR 19.4M·Expired · Jul 06, 2026·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
High valueStructured notice only
Titre original de l'avis

Italy – Antineoplastic and immunomodulating agents – GARA EUROPEA A PROCEDURA APERTA PER LA FORNITURA, IN ACCORDO QUADRO MULTIFORNITORE, DI PRINCIPI ATTIVI PER TERAPIE CON CELLULE CAR-T DESTINATE A PAZIENTI IN CARICO ALL’AZIENDA ULSS N. 8 BERICA

30/100

Score d'opportunité

Needs reviewMedium complexity
SuppliesFrameworkExpired
Pourquoi ce score ?

Opportunité

30 / 100

Complexité

60 / 100

Facteurs de risque

The tender notice (XML) indicates the procedure is suspended due to a complaint (reclamo). Potential outcomes: cancella...

EU funding flag differs between structured data (EU-funded) and XML (no-eu-funds). Also, submission deadline time incon...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Informations clés

Pouvoir adjudicateur
Azienda ULSS n. 8 Berica
Pays
Italie
CPV
33652000 - Antineoplastic and immunomodulating agents
Date limite
Jul 06, 2026
Valeur estimée
EUR 19.4M

Aperçu

Moderate opportunity

Faits clés

  • EUR 19.4M estimated value
  • Framework procurement
  • Supplies contract
  • 3 lots
  • Duration 12 MONTH
  • Supply of active principles (pharmaceutical substances) for CAR-T cell therapies.
  • The products are intended for specific lymphoma indications: DLBCL (2nd and 3rd line), PMBCL (3rd line), and follicular lymphoma (4th line).
Afficher le résumé complet

This is an open procedure tender for a multi-supplier framework agreement for the supply of active principles for CAR-T cell therapies, intended for patients under the care of Azienda ULSS n. 8 Berica (Italy). The tender is divided into three lots covering specific lymphoma therapies. The procedure is currently suspended due to a complaint (reclamo) as per the XML notice. The estimated total value across lots is €19,401,945. Award is based solely on price. Submission deadline is 2026-07-06 (10:00 or 12:00 – inconsistency noted). Important documents (e.g., ESPD) are required. EU funding status is inconsistent between structured data (EU-funded) and XML notice (no EU funds). The notice is in Italian only.

Risques

The tender notice (XML) indicates the procedure is suspended due to a complaint (reclamo). Potential outcomes: cancella...

EU funding flag differs between structured data (EU-funded) and XML (no-eu-funds). Also, submission deadline time incon...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Certifications

  • All communications and submissions must be electronic via Sintel or certified email (PEC) for Italian operators, or qualified electronic registered delivery service for...

Administrative

  • Registration on the Sintel e-procurement platform (ARIA SPA) is mandatory.
  • Tender must be accompanied by the European Single Procurement Document (ESPD) or equivalent.

Les exigences peuvent être incomplètes.

Critères d'attribution

Lot 1

Award criterion: price only (lowest price).

Lot 2

Award criterion: price only (lowest price).

Lot 3

Award criterion: price only (lowest price).

Acheteur

Localisation

Vicenza, ITA

Profil acheteur

Ouvrir le profil

Identifiant

02441500242

Activité

Health

Lots (3)

LOT-0001

LOTTO 1 - Therapy for adult patients with DLBCL Lymphoma - 2nd Line and Therapy for adult patients with PMBCL Lymphoma - 3rd Line

Supply of active principles for CAR-T therapy for adult patients with DLBCL (2nd line) and PMBCL (3rd line). Framework agreement with a maximum value of €15,936,345, including a 12-month initial period and an optional 12-month renewal.

SuppliesFrameworkEU fundedElectronic submission

EUR 19.4M

Valeur estimée

Durée

12 MONTH

Catégorie

Antineoplastic and immunomodulating agents

Critères d'attribution

Price

Date limite

Expired Jul 06, 2026

LOT-0002

LOTTO 2 - Therapy for adult patients with DLBCL Lymphoma - 3rd Line

Supply of active principles for CAR-T therapy for adult patients with DLBCL (3rd line). Framework agreement with a maximum value of €1,732,800, including a 12-month initial period and an optional 12-month renewal.

SuppliesFrameworkEU fundedElectronic submission

EUR 19.4M

Valeur estimée

Durée

12 MONTH

Catégorie

Antineoplastic and immunomodulating agents

Critères d'attribution

Price

Date limite

Expired Jul 06, 2026

LOT-0003

LOTTO 3 - Therapy for adult patients with Follicular Lymphoma (FL) - 4th Line

Supply of active principles for CAR-T therapy for adult patients with follicular lymphoma (4th line). Framework agreement with a maximum value of €1,732,800, including a 12-month initial period and an optional 12-month renewal.

SuppliesFrameworkEU fundedElectronic submission

EUR 19.4M

Valeur estimée

Durée

12 MONTH

Catégorie

Antineoplastic and immunomodulating agents

Critères d'attribution

Price

Date limite

Expired Jul 06, 2026

Détails de la procédure

Date de publication
02 Jul 2026
Langues
Italian

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
456933-2026

Documents (2)

Document de consultation 1Portail de soumission 1

Appels d'offres similaires

Czechia – Specialised chemical products – DNS - chemikálie pro molekulární a buněčnou biologii

Dec 31

Bulgaria – Pharmaceutical products – Доставка на лекарствени продукти за нуждите на КОЦ-Русе ЕООД

Oct 31